Report Scope
This report highlights the current and future market potential for human recombinant DNA and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, trends and key players in the market. The report also provides market projections from 2022 through 2027. An in-depth discussion of strategic alliances, industry structures, competitive dynamics, and market forces are also provided.
Report Includes
- 24 data tables and 8 additional tables
- An overview of the global market for human recombinant DNA
- Estimation of the market size and analyses of global market trends, with data from 2020, 2021 with projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the market potential for human recombinant DNA, based on product, application, and region
- Coverage of history and future of human recombinant DNA, and latest technological advancements of the industry
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
- Coverage of regulatory landscape, product recalls, pipeline products, and discussion on future perspective, strategies, and developments of the industry
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and a relevant patent analysis
- Company profiles of major players within the industry AbbVie Inc., Amgen Inc., Eli Lilly, Sanofi
What is the estimated value of the Global Human Recombinant DNA Market?
What is the growth rate of the Global Human Recombinant DNA Market?
What is the forecasted size of the Global Human Recombinant DNA Market?
Who are the key companies in the Global Human Recombinant DNA Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 84 |
| Published | July 2022 |
| Forecast Period | 2022 - 2027 |
| Estimated Market Value ( USD | $ 348.7 Billion |
| Forecasted Market Value ( USD | $ 496.9 Billion |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 7 |
Table of Contents
Executive Summary
Recombinant DNA technology (RDT) is essential for improving health conditions, primarily by developing new vaccines and pharmaceuticals. The treatment strategies are improved by developing diagnostics kits, monitoring devices and new therapeutic approaches. Additionally, many other industries such as agriculture are benefiting from the research conducted on genetically modified organisms (GMO), for example microorganisms that are considered clean fuel producers and bio degraders.
Advances in oncology research for discovering underlying molecular mechanisms of cancerous cells to develop novel therapeutics is benefitting the market. The rising number of advanced cancer cases worldwide has significantly increased the need for developing DNA damage-response drugs. These drugs can improve cancer survival by providing a selective and well-tolerated treatment approach.
Regulatory approvals that delay product marketing can adversely impact manufacturer revenues. Similarly, a delay in post-approval of a drug product for another therapeutic indication increases clinical trial costs and potentially affects the labeling and approval status of currently marketed products.
Companies Mentioned
- Abbvie Inc.
- Alexion Pharmaceuticals
- Amgen Inc.
- Eli Lilly
- Merck & Co. Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Co Ltd.
